Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AXS-07 · Symbravo

Small molecule · Inhibitor of 5-HT1B receptor (HTR1B), 5-HT1D receptor (HTR1D) and cyclooxygenase-1 (PTGS1) · developed by Axsome

Approved FDA, Jan 2025

AXSM Developer

3 Registered trials

What is AXS-07?

AXS-07 (Symbravo) is a combination of meloxicam, a COX-1 and COX-2 inhibitor, and rizatriptan, a 5-HT1B/1D receptor agonist.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Symbravo
Drug type: Small molecule
Targets: 5-HT1B receptor (HTR1B), 5-HT1D receptor (HTR1D), cyclooxygenase-1 (PTGS1), cyclooxygenase-2 (PTGS2)
Mechanism: Inhibitor of 5-HT1B receptor (HTR1B), 5-HT1D receptor (HTR1D) and cyclooxygenase-1 (PTGS1)
Pathways: prostaglandin synthesis inhibition
Therapy area: Neurology
Developer: Axsome (AXSM)
FDA status: Approved as Symbravo (January 30, 2025), NDA215431 · FDA label

✅ FDA-approved uses

Acute treatment of migraine with or without aura in adults

From the indications section of the FDA label (version of Nov 21, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05550207	Phase 3	Migraine	Completed	AXSM
NCT04163185	Phase 3	Migraine	Completed	AXSM
NCT04068051	Phase 3	Migraine	Completed	AXSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Migraine

Other drugs acting on HTR1B / HTR1D / PTGS1 / PTGS2

Diclofenac FDA approved Ibuprofen FDA approved Ketorolac FDA approved OMS302 FDA approved OMS302-PE FDA approved Phenylephrine And Ketorolac FDA approved Rizatriptan FDA approved STP707 Phase 1

More from Axsome

Dextromethorphan/Bupropion FDA approved Solriamfetol FDA approved AXS-02 Phase 3 AXS-14 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AXSM page.

Follow AXSM, the company behind AXS-07

See AXSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AXSM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z